From the beginning, we do understand how devastating cognitive impairment can be. Neurological disorders are the leading cause of death and disability in the world today with about 1 in 6 people suffering from neurological disorders. These disorders severely disrupt lives and often lead to premature death. It is our responsibility to our contributors to conduct our research studies meticulously, thereby making the entire process and goals easily understood. We want you, the consumer, to know what our studies are about.
Your support is essential to advancing our understanding of neurological illness. Currently, we study Myalgic Encephalomyelitis Syndrome and Chronic Fatigue Syndrome. Your dollars will go to research for better diagnosis and treatment of ME/CFS and other neurological diseases which have a similar etiology.
Planned Research Studies
qEEG and eLORETA activity in CFS/ME
This study is being designed to help improve the speed and accuracy of diagnosis of the Chronic Fatigue Syndrome and Myalgic Encephalomyelitis (CFS/ME) using non-invasive and inexpensive methods for diagnosis of cognitive impairment, which is perhaps the most devastating symptom of this disease.
This case-control observational study will use qEEG methods with eLORETA 3D neuroimaging to evaluate the nature and extent of cognitive impairment in patients. The primary aims of the study are 1) to assess the neuropsychological status of the participants with linkage of symptoms and behavior to functional systems in the brain and 2) ascertain whether qEEG/eLORETA measurement will provide information that will aid practitioners in assessing long-term outcomes of cognitive impairments within CFS/ME.
We will follow the participants in this trial over a number of years to track changes in their health status, and see how those changes affect their overall neurocognitive status. Here, we will learn how the brain changes during the course of Neurocognitive dysfunction and how it related to the underlying medical picture of the participants.
Please check back as we will be adding more research trials.